Auxilium Pharmaceuticals — Investor Presentation (September 2011)
45 slides from Auxilium Pharmaceuticals's investor presentation, Sep 6, 2011
Slide 1: September 2011
September 2011 (NASDAQ: AUXL)
Slide 2: Safe Harbor Statement
Safe Harbor Statement We will make various remarks relating to our current plans, potential future events, and what we believe to be the prospects for the Company during this conference call that constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Secur
Slide 3: Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Biopharmaceutical Company
Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Biopharmaceutical Company Shareholder Value Maximize Value of Testim and XIAFLEX Build Out Pipeline in Specialty Therapeutic Areas Deliver on Current Pipeline
Slide 4: XIAFLEX and Testim Are Global Product Opportunities
XIAFLEX and Testim Are Global Product Opportunities Territory XIAFLEX Testim U.S. Canada EU Japan ROW Open Open Open
Slide 5: Auxilium Has a Year Net Revenue CAGR of 42.5%
Auxilium Has a 6 Year Net Revenue CAGR of 42.5% Net Revenue (000’s) $70,000 $60,000 $50,000 $40,000 $30,000 $20,000 $10,000 $- 2Q11 XIAFLEX Net Revenues $15.4M (including $9.9M in U.S. revenues) 2Q11 Testim Net Revenues $50.5M, 7% y/y growth Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q
Slide 6: Slide 6
Slide 7: Dupuytren's Contracture and Surgery Has Been the Standard of Care
Dupuytren’s Contracture and Surgery Has Been the Standard of Care Excessive collagen in fascia of hand Nodules or pits are an early, active presentation Rope-like cords develop in the finger and result in contractures Quality of life and daily activities affected pre-operative open fasciectomy Intra
Slide 8: We Believe XIAFLEX Is a Paradigm Changing Treatment
We Believe XIAFLEX Is a Paradigm Changing Treatment Pre XIAFLEX injection Simple, non-invasive injection of XIAFLEX Established mechanism of action and selective for specific types of collagen XIAFLEX’s post-approval profile is consistent with clinical trial experience
Slide 9: Strategies for Establishing XIAFLEX as the Standard of Care
Strategies for Establishing XIAFLEX as the Standard of Care Disseminate our excellent clinical efficacy and safety data; Facilitate peer to peer dialogue with physicians and reimbursement specialists; Educate patients and health care providers who inject, as well as those who refer to our target spe
Slide 10: XIAFLEX Launch Strategy is Tailored to Customer Needs
XIAFLEX Launch Strategy is Tailored to Customer Needs ~ 6,000 target physicians – Hand surgeons, plastic surgeons, orthopedic surgeons, general surgeons, rheumatologists ~ 100 field based personnel – Sales reps, sales managers, and reimbursement specialists Medical science liaisons – Key opinion lea
Slide 11: We Believe the U.S. Dupuytren's Opportunity Is Significant
We Believe the U.S. Dupuytren’s Opportunity Is Significant $350 Million Market Opportunity $1 Billion Annual Market Opportunity >$3 Billion Market Opportunity 70,000 Surgical 2,3,4 Patients Annually 300,000 Diagnosed Patients Annually 2,3,4 >1 Million Diagnosed Patients 2,4 Sources: 1. Dupuytren’s D
Slide 12: XIAFLEX U.S. Post-Marketing Safety Experience Comparable to Clinical Trial Experience
XIAFLEX U.S. Post-Marketing Safety Experience Comparable to Clinical Trial Experience Information reported since U.S. approval of XIAFLEX – Feb 2, 2010 to June 30, 2011 Approximately 11,000 injections administered post-approval in the U.S. – Approximately 1.1 injections per patient – Assumption: App
Slide 13: Launch Update Through August 2011
Launch Update Through August 2011
Slide 14: Leading Indicators Trending Positively
Leading Indicators Trending Positively —Cumulative enrollment & sites that have ordered XIAFLEX 3500 3000 2500 2000 1500 1000 500 0 PHYSICIAN ENROLLMENTS SITES ENROLLED UNIQUE SITES ORDERING 2597 2512 2400 2306 2202 2097 1994 1937 1845 1693 1758 1613 1509 1422 983 772 841 902 671 576 500 2974 2885 2
Slide 15: Sites Moving from Test Drive to Increasing Usage
Sites Moving from Test Drive to Increasing Usage Number of Sites 500 450 400 350 300 250 200 150 100 50 0 456 480 460 457 444 451 434 437 438 308 429 407 286 408 372 261 347 229 August (1244 Sites) July (1203 Sites) June (1156 Sites) May (1100 Sites) Apr (1048 Sites) Mar (983 Sites) Feb (902 Sites)
Slide 16: Quarterly XIAFLEX Revenue (in $ millions)
Quarterly XIAFLEX Revenue (in $ millions) $18.0 $16.0 $14.0 $12.0 $10.0 $8.0 $6.0 $4.0 $2.0 $- Q2 2010 Q3 2010 Q4 2010 Q1 2011 Q2 2011 $1.1 $2.0 $1.1 $4.6 $1.1 $7.3 $1.8 $1.8* $8.7 $5.5 $9.9 U.S. Revenues EX- U.S. and Contract Revenues * Includes one-time revenue recognition change of $1.8 million
Slide 17: We Expect the Global Dupuytren's Market to Develop in 2011 and 2012
We Expect the Global Dupuytren’s Market to Develop in 2011 and 2012 U.S. • XIAFLEX specific J-code J0775 effective Jan. 1 • U.S. CPT code guidance expected for Jan. 2012 • Additional phase IV clinical trials • Increasing peer to peer dialogue programs for U.S. physicians • Targeted U.S. patient educ
Slide 18: Testim 1% Testosterone Gel
Testim® 1% Testosterone Gel • Indicated for testosterone replacement therapy in adult males for hypogonadism • Launched in U.S. in 2003 and EU in • >8 yrs of use with established safety and efficacy >~100M daily doses since launch >16 clinical studies involving approx. 1,800 patients • Applied once
Slide 19: Hypogonadism Is an Unmet Need and Under-penetrated Market
Hypogonadism Is an Unmet Need and Under-penetrated Market • 39% of U.S. males over 45 yrs are hypogonadal1 >Less than 10% of affected population receives treatment • Increasing physician and patient education and awareness should result in increased treatment 1 Mulligan T. et al. Int J. Clin Pract 2
Slide 20: Gels Continue to Drive Significant Growth in TRT Marketplace
Gels Continue to Drive Significant Growth in TRT Marketplace 1,400 1,200 1,000 800 600 400 200 ($ in millions) 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 $1,041 $810 $663 $554 $483 $1,149 $451 $390 $892 $302 $685 $210 $545 $439 $118 $371 $334 $77 $281 $49 $59 $198 $117 $35
Slide 21: Testosterone Replacement Therapy Landscape is Changing
Testosterone Replacement Therapy Landscape is Changing New competition in 2011 should help increase overall market Axiron 2% solution Fortesta 2% gel Androgel 1.6% gel Expected further increase in physician and patient education and awareness
Slide 22: XIAFLEX Pipeline
XIAFLEX Pipeline
Slide 23: XIAFLEX Represents a Pipeline in a Product
XIAFLEX® Represents a Pipeline in a Product —U.S. patent protected through 2028 PRODUCT LATE RESEARCH PRE-CLINICAL PHASE I PHASE II PHASE III MARKET XIAFLEX XIAFLEX XIAFLEX XIAFLEX XIAFLEX XIAFLEX Dupuytren’s Peyronie’s Frozen Shoulder Syndrome Canine Lipoma* Human Lipoma* Cellulite* *Right to exerc
Slide 24: Peyronie's disease Is a Devastating Disorder with No Approved Therapies
Peyronie’s disease Is a Devastating Disorder with No Approved Therapies Scarring phenomenon affecting the tunica albuginea1 Plaques show excessive collagen deposition2 Potential Symptoms >Pain with erection, penile curvature/ deviation, penile shortening, indentations, and/or erectile dysfunction >M
Slide 25: We believe Peyronie's Disease Is Under-diagnosed and Under-treated
We believe Peyronie’s Disease Is Under-diagnosed and Under-treated Prevalence of Peyronie’s disease is estimated to be approximately 5% in adult men1,2,3 >Actual prevalence may be higher, based on autopsies4 •Prevalence rate increases with age >The average age of disease onset is 53 years5 •High ass
Slide 26: Peyronie's Disease Phase III Development Program
Peyronie’s Disease Phase III Development Program ~ # XIAFLEX: Study Type Sites Duration Subjects Placebo Double-blind, ~ 30 US AUX-CC-803 400 2:1 52 Wks placebo controlled 5 AUS Double-blind, ~ 30 US AUX-CC-804 400 2:1 52 Wks placebo controlled 5 AUS 12 US AUX-CC-802 Open Label 250 6 NZ N/A 36 Wks 1
Slide 27: Changes to the Phase IIb Trial Design Should Increase the Chance of Success
We Believe Changes to the Phase IIb Trial Design Should Increase the Chance of Success in Phase III 4 cycles of therapy in the phase III trial All patients receive modeling in the phase III trial All patients must have greater than 12 months of disease since diagnosis to enter the phase III trial Me
Slide 28: Peyronie's Pivotal Phase III Update
Peyronie’s Pivotal Phase III Update Active dosing phase complete Entering 34 week follow-up phase of studies Top line results in Peyronie’s should be available in 2Q12
Slide 29: Collagen Septae Enable Edematous Fibrosclerotic Panniculopathy (EFP)
Collagen Septae Enable Edematous Fibrosclerotic Panniculopathy (EFP) Cellulite Collagen Network
Slide 30: EFP Represents an Unmet Medical Need
EFP Represents an Unmet Medical Need • Current non-surgical treatment options have not shown benefit in EFP – OTC pills, creams and lotions. – Unapproved mixtures of enzymes and fat dissolvers – Various devices, including lasers • There are currently no FDA approved medical therapies for EFP • Surgi
Slide 31: Early Pilot Phase I Trial was Encouraging
Early Pilot Phase I Trial was Encouraging • Drs. Dagum and Badalamente at SUNY Stony Brook • 10 female subjects were treated with a single 0.58 mg dose of collagenase • 76% reduction in the physician reported appearance of cellulite and a patient satisfaction score of 1.75 at 6 months – Scale for th
Slide 32: Considerable Work Done in Cellulite
Considerable Work Done in Cellulite Pre-IND meeting with FDA to determine a path forward Pre-clinical work done with subcutaneous injections of XIAFLEX at variable doses in a mini-pig study Lysis of collagen in dermal septae was observed at all doses Completing stability work on new diluent and dosa
Slide 33: Cellulite – Phase Ib Dose Escalation Study
Cellulite – Phase Ib Dose Escalation Study •Expected to begin in 1Q12 •Assess the safety and efficacy of XIAFLEX in the treatment of cellulite –Multiple doses in various volumes and concentrations –10 injection sites over an 8 x 10cm surface area –Seven cohorts followed for 90 days •Physician and pa
Slide 34: Collagen Accumulation Can Result in Adhesive Capsulitis
Collagen Accumulation Can Result in Adhesive Capsulitis Normal Shoulder Frozen Shoulder
Slide 35: Adhesive Capsulitis Represents an Unmet Medical Need
Adhesive Capsulitis Represents an Unmet Medical Need • Current treatment options have limited results – non-steroidal pain relievers – oral steroids – corticosteroid injections – physical therapy all with limited results. • Manipulation of the shoulder under anesthesia or arthroscopic surgery can di
Slide 36: Early Pilot Phase II Trial was Encouraging
Early Pilot Phase II Trial was Encouraging • Drs. Wang and Badalamente at SUNY Stony Brook – 60 subjects treated with varying doses of collagenase – Following a single injection of collagenase, 8 subjects in the collagenase groups or approximately 16% achieved successful treatment outcomes – In the
Slide 37: Frozen Shoulder – Phase IIa Dose Escalation Study
Frozen Shoulder – Phase IIa Dose Escalation Study • To assess the safety and efficacy of XIAFLEX in the treatment of Frozen Shoulder – Two doses (0.29 and 0.58 mg) given under ultrasound guidance – Approximately 50 subjects across 4 cohorts – Up to three injections 21 days apart – Subjects followed
Slide 38: BTC Will Advance Clinical Studies in Canine and Human Lipomas
BTC Will Advance Clinical Studies in Canine and Human Lipomas • Lipomas consist of normal fat encapsulated within a collagen capsule or shell • Current treatment options for lipoma include liposuction or surgical excision • There are no approved non-surgical therapies • We believe XIAFLEX may be ben
Slide 39: XIAFLEX – Additional Data and Development Work Ongoing
XIAFLEX – Additional Data and Development Work Ongoing • Some small pilot studies were conducted examining the effects of collagenase on lipomas in humans and animals. • Investigators noted improvement in lipomas, specifically reduction in their size, following injections of collagenase. • BTC is pl
Slide 40: Business Development Efforts Expected to Focus on Building Out Pipeline
Business Development Efforts Expected to Focus on Building Out Pipeline •Leverage current infrastructure of Testim and XIAFLEX field forces with marketed products •Seeking Phase II and later assets in Urology, Endocrinology, Rheumatology, and Orthopedics •Niche products with specialty physician call
Slide 41: 2Q11 Financial Results ($ Millions)
2Q11 Financial Results ($ Millions) Incr. /(Decr.) 2Q11 2Q10 $% Total Revenues $ 65.9 $ 50.5 $15.5 31% Cost of Goods Sold * $ 14.4 $ 11.5 $ 2.8 25% Gross Profit $ 51.6 $ 39.0 $ 12.6 32% % of Revenues 78% 77% R & D Expense * $ 13.3 $ 11.1 $ 2.2 20% SG&A Expense * $ 43.4 $ 41.2 $ 2.1 5% Net Loss $(5.1
Slide 42: 2011 Guidance
2011 Guidance Global Testim Revenues $200—210 million Xiaflex: US Revenues 45—50 million Ex US / Def Rev 9—11 million Total Xiaflex $54—61 million Total Revenues $254 –271 million R & D Expense $60—70 million S G & A Expense $170—180 million Net Income (Loss) $(40) -(45) million Stock Base Comp Expe
Slide 43: We Believe That Auxilium is Well-Positioned for Long-Term Growth
We Believe That Auxilium is Well-Positioned for Long-Term Growth Establish XIAFLEX as the standard of care for Dupuytren’s contracture in the U.S. •Maximize Testim in a changing competitive environment •Support Pfizer’s launch of XIAPEX for the treatment of Dupuytren’s contracture •Complete the Peyr
Slide 44: Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Biopharmaceutical Company
Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Biopharmaceutical Company Shareholder value Maximize Value of Testim and XIAFLEX Deliver on Current Pipeline Build Out Pipeline in Specialty Therapeutic Areas
Slide 45: Management Contact
Management Contact James E. Fickenscher/CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 jfickenscher@auxilium.com William Q. Sargent Jr./ VP IR Auxilium Pharmaceuticals, Inc. (484) 321-5900 wsargent@auxilium.com
Auxilium Pharmaceuticals — Investor Presentation (September 2011) on 6ix